Lates News

According to a research report released by Open Source Securities on November 10th, Xinghao Pharmaceuticals (920017.SH) was rated as "buy". The reasons for the rating mainly include: 1) From 2025 Q1 to Q3, revenue reached 475 million yuan, a year-on-year increase of 1%, with a net profit attributable to the parent company of 86.25 million yuan, a year-on-year increase of 10%; 2) The orally disintegrating tablets of Sildenafil Citrate (freeze-dried type) have been approved for market launch, and commercial promotion of injectable trypsin has begun; 3) In 2024, the sales of pharmaceuticals in China's three major end markets and six major markets reached 1.8638 trillion yuan, with public hospitals accounting for 60% of the end markets. (Daily Economic News)